Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07643220

Bioequivalence Study of AJU-G721 and G721R in Healthy Adult Volunteers Under Fasting Conditions

To evaluate and compare the safety and pharmacokinetic profiles of "AJU-G721" (test drug) and "G721R" (reference drug) in healthy adult male subjects.

Recruiting

Interested in participating?

Request Info

Key information

Age range

19 year–54 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy male adults aged ≥19 years and <55 years at screening.
  • Body weight ≥ 50 kg and body mass index (BMI) between 18 and 30 kg/m².
  • Clinically healthy based on medical history, physical examination, ECG, and laboratory test results, as determined by the investigator.
  • Willing and able to provide written informed consent.
  • Agrees to use medically acceptable contraception during the required study period.

Exclusion criteria

  • Use of medications known to induce or inhibit drug-metabolizing enzymes within 30 days prior to the first dose, or other medications that may interfere with the study within 10 days prior to dosing.
  • Participation in another clinical trial involving an investigational product within 6 months prior to the first dose.
  • Whole blood donation within 8 weeks or component blood donation within 2 weeks prior to the first dose.
  • History of gastrointestinal resection that may affect drug absorption.
  • Known hypersensitivity to dutasteride, tamsulosin, or any component of the investigational product.
  • History of psychiatric illness, or any condition considered unsuitable for study participation by the investigator.

Treatment and study plan

Test Drug

Drug

AJU-G721

Reference Drug

Drug

G721R

Primary outcomes

  1. Cmax of Dutasteride and Tamsulosin.

    Time frame: [Time Frame: 0 hour ~ 72 hour after drug administration]

    To assess the maximum observed plasma concentration (Cmax) of Dutasteride and Tamsulosin.

  2. AUCt of Dutasteride and Tamsulosin

    Time frame: [Time Frame: 0 hour ~ 72 hour after drug administration]

    To assess the plasma concentration-time curve from time 0 to the last measurable concentration (AUCt) of Dutasteride and Tamsulosin

Sponsors and collaborators

Lead sponsor

AJU Pharm Co., Ltd.

Industry

Registry information

Official study title

An Open-Label, Randomized, Fasting, Single-Dose, Two-Sequence, Two-Period Crossover Study to Evaluate the Bioequivalence of "AJU-G721" and "G721R" in Healthy Adult Male Subjects

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jun 11, 2026
Registry last updated
Jun 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.